A Phase 4 interventional study of celecoxib and Ibuprofen in Arthritis, Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1,066 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 2nd largest by enrollment of the 771 interventional ones that give a count, is one of 35 that started in 2006, is one of 61 in phase 4, and was the 121st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 35 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24,081 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 802 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
Drug: celecoxib
subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
Drug: Ibuprofen
subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
Drug: Naproxen
The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology).
Time frame: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
The First Occurrence of a Major Adverse Cardiovascular Events (MACE)
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
Time frame: ITT Population - 30 months; MITT Population - 42 months
The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer
Time frame: ITT Population - 30 months; MITT Population - 42 months
Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)
VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain".
Time frame: ITT and MITT Population - Baseline to 42 months
The study was conducted at 950 centers in Australia (11), Brazil (30), Canada (64), Colombia (7), Costa Rica (12), Hong Kong (4), Mexico (11), Panama (2), Peru (5), Philippines (8), Taiwan (10), Ukraine 19), and United States (767); a total of 24 sites were activated but did not randomized any subject.
| Milestone | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| Started | 8072 | 8040 | 7969 |
| Completed | 5664 | 5580 | 5621 |
| Not completed | 2408 | 2460 | 2348 |
| Withdrew: Other | 181 | 231 | 205 |
| Withdrew: No longer willing to participate | 600 | 606 | 585 |
| Withdrew: Withdrawal by subject | 661 | 692 | 651 |
| Withdrew: Lost to follow-up | 611 | 588 | 542 |
| Withdrew: Physician decision | 80 | 76 | 59 |
| Withdrew: Does not meet entrance criteria | 13 | 10 | 8 |
| Withdrew: Death | 189 | 192 | 228 |
| Withdrew: Study terminated by sponsor | 11 | 4 | 8 |
| Withdrew: Missing subject summary status | 62 | 61 | 62 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology).
| Percentage of Partcipants | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| ITT (N = 8072, 8040, 7969) | 2.3 | 2.7 | 2.5 |
| MITT (N = 8030, 7990, 7933) | 1.7 | 1.9 | 1.8 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
| Percentage of Participants | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| ITT (N = 8072, 8040, 7969) | 4.2 | 4.8 | 4.3 |
| MITT (N = 8030, 7990, 7933) | 3.1 | 3.6 | 3.2 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer
| Percentage of Participants | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| ITT (N = 8072, 8040, 7969) | 0.7 | 0.9 | 0.7 |
| MITT (N = 8030, 7990, 7933) | 0.3 | 0.7 | 0.7 |
VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain".
| Number of participants | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | 54.0 ± 23.53 | 54.1 ± 23.58 | 54.1 ± 24.04 |
| Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | -8.2 ± 24.69 | -9.0 ± 25.69 | -9.9 ± 25.53 |
| Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | -10.5 ± 26.39 | -10.6 ± 26.92 | -11.1 ± 26.83 |
| Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | -11.4 ± 27.70 | -11.7 ± 28.10 | -12.3 ± 27.80 |
| Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | -11.7 ± 28.92 | -12.1 ± 28.97 | -12.1 ± 28.83 |
| Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | -11.0 ± 29.15 | -11.6 ± 29.29 | -11.9 ± 29.30 |
| Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | -11.3 ± 29.11 | -11.3 ± 29.10 | -11.7 ± 29.33 |
| Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | -11.3 ± 29.44 | -11.5 ± 28.98 | -11.4 ± 29.27 |
| Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | -10.5 ± 29.81 | -11.2 ± 29.71 | -11.3 ± 29.71 |
| Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | -10.1 ± 29.61 | -10.7 ± 29.62 | -11.6 ± 29.80 |
| Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | -11.4 ± 29.78 | -11.1 ± 30.14 | -12.1 ± 30.27 |
| Baseline (MITT) N=7974, 7954, 7894 | 54.0 ± 23.53 | 54.1 ± 23.58 | 54.1 ± 24.02 |
| Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | -8.2 ± 24.69 | -9.0 ± 25.67 | -9.9 ± 25.53 |
| Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | -10.5 ± 26.38 | -10.6 ± 26.92 | -11.1 ± 26.84 |
| Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | -11.4 ± 27.70 | -11.7 ± 28.10 | -12.3 ± 27.81 |
| Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | -11.7 ± 28.93 | -12.1 ± 28.97 | -12.1 ± 28.84 |
| Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | -11.0 ± 29.16 | -11.6 ± 29.30 | -11.9 ± 29.30 |
| Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | -11.3 ± 29.11 | -11.3 ± 29.12 | -11.7 ± 29.33 |
| Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | -11.4 ± 29.44 | -11.5 ± 29.00 | -11.3 ± 29.26 |
| Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | -10.5 ± 29.81 | -11.2 ± 29.71 | -11.3 ± 29.70 |
| Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | -10.2 ± 29.61 | -10.7 ± 29.62 | -11.6 ± 29.80 |
| Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | -11.4 ± 29.78 | -11.1 ± 30.14 | -12.1 ± 30.27 |
Collected over Adverse events were reported from the signing of the informed consent throughout the entire study period (42 months) and including 30 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 1,473/8,030 (18.3%) | 4,268/8,030 (53.2%) |
| Ibuprofen | — | 1,624/7,992 (20.3%) | 4,363/7,992 (54.6%) |
| Naproxen | — | 1,611/7,933 (20.3%) | 4,337/7,933 (54.7%) |
| Event | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 201/8030 | 206/7992 | 189/7933 |
| Chest painGeneral disorders | 52/8030 | 84/7992 | 73/7933 |
| PneumoniaInfections and infestations | 64/8030 | 79/7992 | 69/7933 |
| Myocardial infarctionCardiac disorders | 45/8030 | 70/7992 | 48/7933 |
| Angina unstableCardiac disorders | 45/8030 | 41/7992 | 60/7933 |
| Coronary artery diseaseCardiac disorders | 42/8030 | 40/7992 | 44/7933 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 44/8030 | 33/7992 | 39/7933 |
| Cardiac failure congestiveCardiac disorders | 31/8030 | 41/7992 | 41/7933 |
| Atrial fibrillationCardiac disorders | 35/8030 | 39/7992 | 36/7933 |
| Acute kidney injuryRenal and urinary disorders | 36/8030 | 39/7992 | 31/7933 |
| Event | Celecoxib | Ibuprofen | Naproxen |
|---|---|---|---|
| HypertensionVascular disorders | 762/8030 | 1008/7992 | 855/7933 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 958/8030 | 859/7992 | 880/7933 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 764/8030 | 659/7992 | 764/7933 |
| DiarrhoeaGastrointestinal disorders | 641/8030 | 538/7992 | 566/7933 |
| Upper respiratory tract infectionInfections and infestations | 584/8030 | 595/7992 | 560/7933 |
| Back painMusculoskeletal and connective tissue disorders | 542/8030 | 516/7992 | 547/7933 |
| NauseaGastrointestinal disorders | 425/8030 | 482/7992 | 502/7933 |
| BronchitisInfections and infestations | 465/8030 | 471/7992 | 427/7933 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 455/8030 | 422/7992 | 422/7933 |
| Urinary tract infectionInfections and infestations | 416/8030 | 452/7992 | 414/7933 |
| Age, Continuous(Years) | Celecoxib | Ibuprofen | Naproxen | Total |
|---|---|---|---|---|
| Mean | 63.0 ± 9.5 | 63.2 ± 9.4 | 63.3 ± 9.4 | 63.2 ± 9.4 |
| Sex: Female, Male(Participants) | Celecoxib | Ibuprofen | Naproxen | Total |
|---|---|---|---|---|
| Female | 5175 | 5174 | 5096 | 15445 |
| Male | 2897 | 2866 | 2873 | 8636 |
Showing the first 100 of 1,066 sites across 13 countries. Choose a country and city above to see the rest.
Ran from Oct 2006 to primary completion in Apr 2016, 114 months.
Results were first posted in May 2017, 1 year after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 114 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →